Colin Bristow
Stock Analyst at UBS
(1.74)
# 3,378
Out of 5,152 analysts
105
Total ratings
40.32%
Success rate
-1.33%
Average return
Main Sectors:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Maintains: Neutral | $4 → $10 | $8.71 | +14.81% | 3 | Nov 12, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $553 → $546 | $460.82 | +18.48% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $108 → $112 | $145.14 | -22.83% | 4 | Aug 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $71 → $80 | $63.33 | +26.32% | 4 | Jul 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $4.64 | +7.76% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $2.13 | -53.05% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $26.72 | -36.38% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $367.60 | -13.22% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $3.34 | +19.76% | 4 | Mar 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $26.61 | +5.22% | 13 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $120 | $116.07 | +3.39% | 7 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $188.08 | +7.40% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.61 | +893.79% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $764.93 | +43.67% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $16.23 | +928.96% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $983.26 | -57.28% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $11.49 | -82.59% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.35 | +665.96% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $232.35 | -37.16% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $60.74 | +23.48% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.03 | +758.09% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.85 | +85.57% | 1 | Aug 23, 2021 |
enGene Holdings
Nov 12, 2025
Maintains: Neutral
Price Target: $4 → $10
Current: $8.71
Upside: +14.81%
Vertex Pharmaceuticals
Nov 7, 2025
Maintains: Buy
Price Target: $553 → $546
Current: $460.82
Upside: +18.48%
Gilead Sciences
Aug 8, 2025
Maintains: Neutral
Price Target: $108 → $112
Current: $145.14
Upside: -22.83%
PTC Therapeutics
Jul 29, 2025
Maintains: Buy
Price Target: $71 → $80
Current: $63.33
Upside: +26.32%
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $4.64
Upside: +7.76%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $2.13
Upside: -53.05%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $26.72
Upside: -36.38%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $367.60
Upside: -13.22%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $3.34
Upside: +19.76%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $26.61
Upside: +5.22%
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $116.07
Upside: +3.39%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $188.08
Upside: +7.40%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.61
Upside: +893.79%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $764.93
Upside: +43.67%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $16.23
Upside: +928.96%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $983.26
Upside: -57.28%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $11.49
Upside: -82.59%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $2.35
Upside: +665.96%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $232.35
Upside: -37.16%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $60.74
Upside: +23.48%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.03
Upside: +758.09%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $4.85
Upside: +85.57%